Immunotherapy in Oncology: Groundbreaking Outcomes, Earth-Shattering Costs - Archive

About Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted adviser to many of the world’s leading pharmaceutical, biotech and medical device and diagnostic companies. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.

Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Our advisory services, built on a solid foundation of market research and data, span three areas critical to bringing new medicines and pharmaceutical products to market – commercial development, clinical strategies and marketing effectiveness.

Kantar Health operates in more than 40 countries and employs more than 600 healthcare industry specialists and practitioners, including a high number of medical doctors, epidemiologists, PhDs, PharmDs and pharmacists, and biologists, biochemists and biophysicists. We work across the product lifecycle, from preclinical development to launch, and are experts at bringing multiple stakeholders together to advance the commercialization of pharmaceutical products. Our team acts as catalysts to successful decision making in the life sciences industry, helping our clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. Kantar Health is part of Kantar, the data investment management division of WPP.

If you would like us to act as catalysts for you, contact us at www.kantarhealth.com/contactus.

Immunotherapy in Oncology: Groundbreaking Outcomes, Earth-Shattering Costs - Archive

In this webinar, “Immunotherapy in Oncology: Groundbreaking Outcomes, Earth-Shattering Costs,” Kantar Health examines the awareness of and expectations around immunotherapies, likely evolution of management techniques, and the perceived value of immunotherapy agents. Immunotherapy is giving physicians and payers more treatment options for oncology patients and the oncology treatment landscape is capturing just the tip of the iceberg in terms of development of immunotherapies. These advances are not without cost and with the anticipation of indication expansion, new entrants and combination therapies, many are questioning the sustainability of funding treatment. Debbie Warner will be joined by Dean Gesme, MD and Gary Owens, MD on a panel that will share and discuss business issues and provide both the provider and the payer perspectives on this promising and transformational new therapy.

Watch the Webinar

Panelists:


Dean Gesme, MD
Dean Gesme, MD
President
Minnesota Oncology
Gary Owens, MD
Gary Owens, MD
President, Gary Owens Associates
Medical Management and Pharmaceutical Consultant
Debbie Warner
Debbie Warner
Vice President, Oncology Commercial Strategies
Kantar Health

Moderated By:


Don Sharpe
Don Sharpe
President
OBR